Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to ...

Neuraly and Enigma Biomedical have signed an agreement for PMI04, a positron emission tomography (PET) imaging biomarker for ...

Niagara Falls, NY, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT ...

This is just a sampling of medical advancements in 2024 chosen for their common presence in the American population. It is ...

PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...

Sutter Health, OSF HealthCare, University Hospitals and others are entering expensive, long-term partnerships for key devices ...

Explore the applications of preclinical MRI in neurological diseases, focusing on functional and metabolic imaging techniques ...

Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission ...

Rising adoption of companion animals and demand for ultrasound as quick and affordable as quick and affordable imaging tool for <a target= ...

Explore how MRI imaging acts as a pivotal scientific hub, bridging the gap between preclinical and clinical research to drive ...

The multimodality imaging segment emerged as the largest contributor to the global molecular imaging market in 2021. Additionally, the imaging agents market is categorized into antibodies, aptamers, ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive ...